Expression and targeting of transcription factor ATF5 in dog gliomas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Activating transcription factor 5 (ATF5) is a transcription factor that is highly expressed in undifferentiated neural progenitor/stem cells as well as a variety of human cancers including gliomas. Aims: In this study, we examined the expression and localization of ATF5 protein in canine gliomas, and targeting of ATF5 function in canine glioma cell lines. Materials and Methods: Paraffin-embedded canine brain glioma tissue sections and western blots of tumours and glioma cells were immunoassayed with anti-ATF5 antibody. Viability of glioma cells was tested with a synthetic cell-penetrating ATF5 peptide (CP-d/n ATF5) ATF5 antagonist. Results: ATF5 protein expression was in the nucleus and cytoplasm and was present in normal adult brain and tumour samples, with significantly higher expression in tumours as shown by western immunoblotting. CP-d/n ATF5 was found to decrease cell viability in canine glioma cell lines in vitro in a dose-dependent manner. Conclusion: Similarities in expression of ATF5 in rodent, dog and human tumours, and cross species efficacy of the CP-d/n ATF5 peptide support the development of this ATF5-targeting approach as a novel and translational therapy in dog gliomas.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2017

Fingerprint

Activating Transcription Factors
Glioma
Transcription Factors
transcription factors
Dogs
dogs
Canidae
neoplasms
Neoplasms
Cell Survival
stem cells
Western Blotting
cell lines
Artificial Cells
peptides
Cell Line
therapy dogs
Peptides
brain
Neural Stem Cells

Keywords

  • Astrocytoma
  • Brain tumour
  • Canine glioma cell lines
  • Cell-penetrating peptide
  • D/n-ATF5
  • Oligodendroglioma

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{11cbb7c000e341268f6aa9563c723203,
title = "Expression and targeting of transcription factor ATF5 in dog gliomas",
abstract = "Background: Activating transcription factor 5 (ATF5) is a transcription factor that is highly expressed in undifferentiated neural progenitor/stem cells as well as a variety of human cancers including gliomas. Aims: In this study, we examined the expression and localization of ATF5 protein in canine gliomas, and targeting of ATF5 function in canine glioma cell lines. Materials and Methods: Paraffin-embedded canine brain glioma tissue sections and western blots of tumours and glioma cells were immunoassayed with anti-ATF5 antibody. Viability of glioma cells was tested with a synthetic cell-penetrating ATF5 peptide (CP-d/n ATF5) ATF5 antagonist. Results: ATF5 protein expression was in the nucleus and cytoplasm and was present in normal adult brain and tumour samples, with significantly higher expression in tumours as shown by western immunoblotting. CP-d/n ATF5 was found to decrease cell viability in canine glioma cell lines in vitro in a dose-dependent manner. Conclusion: Similarities in expression of ATF5 in rodent, dog and human tumours, and cross species efficacy of the CP-d/n ATF5 peptide support the development of this ATF5-targeting approach as a novel and translational therapy in dog gliomas.",
keywords = "Astrocytoma, Brain tumour, Canine glioma cell lines, Cell-penetrating peptide, D/n-ATF5, Oligodendroglioma",
author = "Daniel York and Sproul, {C. D.} and N. Chikere and Dickinson, {Peter J} and Angelastro, {James M}",
year = "2017",
doi = "10.1111/vco.12317",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Expression and targeting of transcription factor ATF5 in dog gliomas

AU - York, Daniel

AU - Sproul, C. D.

AU - Chikere, N.

AU - Dickinson, Peter J

AU - Angelastro, James M

PY - 2017

Y1 - 2017

N2 - Background: Activating transcription factor 5 (ATF5) is a transcription factor that is highly expressed in undifferentiated neural progenitor/stem cells as well as a variety of human cancers including gliomas. Aims: In this study, we examined the expression and localization of ATF5 protein in canine gliomas, and targeting of ATF5 function in canine glioma cell lines. Materials and Methods: Paraffin-embedded canine brain glioma tissue sections and western blots of tumours and glioma cells were immunoassayed with anti-ATF5 antibody. Viability of glioma cells was tested with a synthetic cell-penetrating ATF5 peptide (CP-d/n ATF5) ATF5 antagonist. Results: ATF5 protein expression was in the nucleus and cytoplasm and was present in normal adult brain and tumour samples, with significantly higher expression in tumours as shown by western immunoblotting. CP-d/n ATF5 was found to decrease cell viability in canine glioma cell lines in vitro in a dose-dependent manner. Conclusion: Similarities in expression of ATF5 in rodent, dog and human tumours, and cross species efficacy of the CP-d/n ATF5 peptide support the development of this ATF5-targeting approach as a novel and translational therapy in dog gliomas.

AB - Background: Activating transcription factor 5 (ATF5) is a transcription factor that is highly expressed in undifferentiated neural progenitor/stem cells as well as a variety of human cancers including gliomas. Aims: In this study, we examined the expression and localization of ATF5 protein in canine gliomas, and targeting of ATF5 function in canine glioma cell lines. Materials and Methods: Paraffin-embedded canine brain glioma tissue sections and western blots of tumours and glioma cells were immunoassayed with anti-ATF5 antibody. Viability of glioma cells was tested with a synthetic cell-penetrating ATF5 peptide (CP-d/n ATF5) ATF5 antagonist. Results: ATF5 protein expression was in the nucleus and cytoplasm and was present in normal adult brain and tumour samples, with significantly higher expression in tumours as shown by western immunoblotting. CP-d/n ATF5 was found to decrease cell viability in canine glioma cell lines in vitro in a dose-dependent manner. Conclusion: Similarities in expression of ATF5 in rodent, dog and human tumours, and cross species efficacy of the CP-d/n ATF5 peptide support the development of this ATF5-targeting approach as a novel and translational therapy in dog gliomas.

KW - Astrocytoma

KW - Brain tumour

KW - Canine glioma cell lines

KW - Cell-penetrating peptide

KW - D/n-ATF5

KW - Oligodendroglioma

UR - http://www.scopus.com/inward/record.url?scp=85019058390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019058390&partnerID=8YFLogxK

U2 - 10.1111/vco.12317

DO - 10.1111/vco.12317

M3 - Article

C2 - 28480569

AN - SCOPUS:85019058390

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -